Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.

Axena Health's collaboration with Mayo Clinic enriches the Leva app with educational content on urinary incontinence and bladder health. The Leva Pelvic Health System, FDA-cleared, offers real-time ...

The FDA has granted fast track designation for TRE-515 in combination with 177 Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) for the treatment of metastatic castration-resistant ...

Treatment of non-metastatic hormone-sensitive prostate cancer (nmHSPC) with enzalutamide (Xtandi) in combination with leuprolide acetate was associated with significantly improved overall survival (OS ...

Anne K. Schuckman, MD, discusses some of the current challenges in delivering optimal care for patients with non–muscle invasive bladder cancer.

A recent study in JAMA Network Open found that although trimodal therapy (TMT) improved quality of life for patients with muscle-invasive bladder cancer, it was not as cost-effective as radical ...

On June 18, 2025, the FDA granted clearance to Neuspera Medical’s integrated sacral neuromodulation (iSNM) system for the treatment of patients with urinary urge incontinence. 1 In this video, Andrea ...

Patient enrollment has been completed for the phase 3 UTOPIA trial (NCT06331299) evaluating UGN-103 (mitomycin) for intravesical solution for the treatment of recurrent low-grade intermediate risk non ...

The uniqueness of this study lies in its focus on NMIBC, as the role of ctDNA is well-established in more advanced diseases but less so in the non–muscle invasive space, where systemic circulating ...

Johnson & Johnson has submitted an application to the European Medicine’s Agency (EMA) seeking an expanded indication for niraparib and abiraterone acetate (Akeega) with prednisone or prednisolone to ...

Zelenectide pevedotin plus pembrolizumab demonstrated a 65% objective response rate in cisplatin-ineligible urothelial carcinoma patients. The combination treatment was generally tolerable, with ...

The FDA granted 510(k) clearance to the Glean Urodynamics System for lower urinary tract dysfunction, enabling wireless, catheter-free monitoring. Darolutamide received FDA approval for metastatic ...